g Because studies showed similar viral suppression with lower raltegravir doses and because Asians usually have high antiretroviral concentrations, we explored low-dose raltegravir therapy in Thais. Nineteen adults on raltegravir at 400 mg twice daily (BID) with HIV RNA loads of <50 copies/ml were randomized to receive 400 mg once daily (QD) or 800 mg QD for 2 weeks, followed by the other dosing for 2 weeks. Intensive pharmacokinetic analyses were performed, and HIV RNA was monitored. Two patients were excluded from the 400-mg QD analysis due to inevaluable pharmacokinetic data. The mean patient weight was 58 kg. Mean pharmacokinetic values were as follows: for raltegravir given at 400 mg BID, the area under the concentration-time curve from 0 to 12 h (AUC 0-12 ) was 15.6 mg/liter-h and the minimum plasma drug concentration (C trough ) was 0.22 mg/liter; for raltegravir given at 800 mg QD, the AUC 0-24 was 33.6 mg/liter-h and the C trough was 0.06 mg/liter; and for raltegravir given at 400 mg QD, the AUC 0-24 was 18.6 mg/liter-h and the C trough was 0.08 mg/liter. The HIV RNA load was <50 copies/ml at each dose level. Compared to the adjusted AUC 0-24 for Westerners on raltegravir at 400 mg BID, Thais on the same dose had double the AUC 0-24 and those on raltegravir at 400 mg QD had a similar AUC 0-24 . More patients had a C trough of <0.021 mg/liter on raltegravir at 400 mg QD (9/17 patients) than on raltegravir at 800 mg QD (1/19 patients) or 400 mg BID (0/19 patients). Seventeen patients used raltegravir at 400 mg QD for a median of 35 weeks; two had confirmed HIV RNA loads between 50 and 200 copies/ml, and both had low C trough values. Low-dose raltegravir could be a cost-saving option for maintenance therapy in Asians or persons with low body weight. However, raltegravir at 400 mg QD was associated with a low C trough and with a risk for HIV viremia. Raltegravir at 200 or 300 mg BID should be studied, but new raltegravir formulations will be needed.
R
altegravir is an HIV-1 integrase strand inhibitor with potency against wild-type and multidrug-resistant viruses (5, 19) . It is approved for use as part of first-line and salvage therapy in treatment guidelines, at a dosage of 400 mg twice daily (BID) (7, 9, 21) , based on large phase III trials showing favorable efficacy and safety profiles in both treatment-naïve (12) and treatment-experienced (20) patients. Phase II studies have shown raltegravir dosages ranging from 200 mg to 600 mg BID to be no different in antiviral activity in treatment-naïve and -experienced patients (10, 14, 15, 19) . Worldwide, raltegravir is most needed for salvage therapy, but even in this setting, it is rarely available, due mainly to its high cost (11) . Antiretroviral dose reduction has been one of the options used in Thailand to decrease cost and increase access. Several studies have shown that Thai adults and children on low-dose antiretroviral regimens achieve comparable pharmacokinetic parameters and treatment outcomes to those of Westerners on standard doses (2, 3, 6, 13, 17) . Therefore, we conducted this study to evaluate the pharmacokinetics of low-dose, once-daily raltegravir (400 mg QD) in HIV-1-infected Thai adults. In addition, we evaluated the pharmacokinetics of raltegravir at 800 mg QD, which would provide a more convenient once-daily regimen with the same total daily raltegravir dose as the standard dosing of 400 mg BID. We assessed the virologic response by using a raltegravir minimum plasma drug concentration (C trough ) threshold of 0.021 mg/liter, which was reported in the QDMRK study to be associated with virologic failure risk (8, 23) .
(This study was presented as an oral discussion and poster presentation at the 18th Conference on Retroviruses and Opportunistic Infections, 27 February to 2 March 2011, Boston, MA.)
MATERIALS AND METHODS
This was a single-center, open-label, crossover design study conducted at the HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT) in Bangkok, Thailand (www.clinicaltrials.gov study no. NCT01159132). The study was approved by the Chulalongkorn University Institutional Review Board, and all patients gave written informed consent before enrollment.
HIV-1-infected adult Thai patients (over 18 years of age) who were on raltegravir at 400 mg BID for at least 3 months and had HIV RNA loads of Ͻ50 copies/ml were enrolled. After screening, all were monitored on days 1, 15, and 29. A medical history evaluation, physical examination, and laboratory analyses were performed at all visits. The laboratory analyses included clinical chemistry, hematology, urinalysis, pregnancy test, CD4 cell count, and HIV RNA load determination. All patients underwent 3 intensive raltegravir pharmacokinetic evaluations for dosing of 400 mg BID, 400 mg QD, and 800 mg QD, but in different orders according to randomization. A block randomization was used, stratifying for whether the subject's regimen included atazanavir. After sample collection for the first intensive pharmacokinetic evaluation on day 1, all patients were randomized to either arm A or arm B. Patients in arm A received raltegravir at 400 mg QD, and those in arm B received raltegravir at 800 mg QD, for 14 days. On day 15, a second intensive pharmacokinetic evaluation was carried out, after which the patients crossed over to the other study arm. Patients in arm A received raltegravir at 800 mg QD, and those in arm B received raltegravir at 400 mg QD, for another 14 days. On day 29, a third intensive pharmacokinetic evaluation was carried out, after which all patients switched back to the initial regimen of raltegravir at 400 mg BID.
Pharmacokinetics. The intensive pharmacokinetic evaluations were performed on days 1, 15, and 29. On all 3 pharmacokinetic study days, patients took their medicine after breakfast, with direct observation from the study nurse. On day 1 (BID dose), 6 ml of blood was collected into a lithium heparin tube predose and at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, and 12.0 h postdosing, and on days 15 and 29 (QD dose), an additional sample was collected at 24 h postdosing. Blood samples were then centrifuged at 3,000 rpm for 10 min at 20°C. Plasma was transferred to a polypropylene tube and stored at Ϫ20°C until analysis (no longer than 1 month), after which all samples were transferred to Ϫ80°C for long-term storage. Raltegravir concentrations were determined by using a validated high-performance liquid chromatography method with fluorescence detection (22) . The raltegravir calibration curve was linear over the concentration range of 0.014 to 10.0 mg/liter, and the lower limit of quantification was 0.014 mg/liter.
Pharmacokinetic parameters were calculated using WinNonlin software, version 5.2 (Pharsight Corporations, Mountain View, CA). The following pharmacokinetic parameters were determined using noncompartmental analysis: area under the plasma concentration-time curve from 0 to 12 h (AUC 0-12 ), AUC 0-24 , the maximum plasma drug concentration (C max ), C trough at 12 h (C 12 ) and 24 h (C 24 ), the time to reach the maximum plasma drug concentration (T max ), and the apparent elimination half-life (t 1/2 ).
Procedures after completion of pharmacokinetic study. After completing the pharmacokinetic evaluations, all patients were followed in the HIV-NAT 006 long-term cohort study (www.clinicaltrials.gov study no. NCT00411983) and continued on standard raltegravir at 400 mg BID as part of their antiretroviral regimens. Patients whose pharmacokinetic values for raltegravir at 400 mg QD fulfilled the protocol-defined target AUC of Ն4.0 h-mg/liter, an exposure deemed to be adequate for viral suppression (4), were offered raltegravir at 400 mg QD. Patients had adherence counseling and HIV RNA monitoring every 3 months. They were informed about the QDMRK results, when they became available, showing raltegravir at 800 mg QD to be associated with more virologic failure than raltegravir at 400 mg BID in antiretroviral-naïve adults (8) , and all elected to continue raltegravir at 400 mg QD. More intensive HIV RNA monitoring every 1 to 2 months was performed, and C trough determinations were repeated. Patients were switched back to raltegravir at 400 mg BID immediately for confirmed HIV RNA loads above 50 copies/ml. Statistical analysis. Statistical analyses were performed using Stata 11.0 (Statacorp, College Station, TX). Comparison of pharmacokinetic parameters was assessed using a random effects regression model adjusting for patient and order of regimen, with maximum likelihood estimation. The geometric mean of each pharmacokinetic parameter was used as the outcome variable in all regression models. In univariate models, dose regimens were modeled with the BID regimen as the reference group. Other potential explanatory covariates included gender, age, weight, estimated creatinine clearance by the Cockroft-Gault formula, plasma alanine aminotransferase (ALT) concentration, and whether the patient was taking tenofovir, darunavir-ritonavir, lopinavir-ritonavir, or atazanavir. The exponentiated regression coefficients presented in our paper correspond to changes in the ratio of the expected geometric means of the outcome variable. Parameters that were significant in the univariate analysis, with P values of Յ0.1, were included in multivariate models, and a backwards stepwise selection procedure was used to select the final model, retaining covariates at a significance level of 0.05. In making comparisons of the AUC between BID and QD regimens, the AUC 0-12 for the BID regimens was first converted to an AUC 0-24 . C trough refers to C 12 for BID regimens and to C 24 for QD regimens. Formal comparisons with the pharmacokinetic parameters for Caucasians taking raltegravir at 400 mg BID reported by Markowitz et al. (14) were made by using the ttesti command in Stata and estimating the geometric standard deviation (SD) from the 95% confidence interval (CI) around the geometric mean, which were provided by Merck. The number of patients with HIV RNA loads of Ͼ50 copies/ml after treatment with raltegravir at 400 mg QD was summarized according to the C trough value during the intensive pharmacokinetic study. The median (IQR) time on raltegravir at 400 mg BID at enrollment was 90 (66 to 110) weeks. All patients were on raltegravir as part of their third-line regimen with a protease inhibitor (PI). The antiretroviral drugs coadministered with raltegravir were lamivudine (n ϭ 18), tenofovir (n ϭ 9), darunavir-ritonavir (n ϭ 11), lopinavir-ritonavir (n ϭ 6), and atazanavir without ritonavir (n ϭ 2). None of the patients was on a nonnucleoside reverse transcriptase inhibitor (NNRTI). No patients dropped out of the study.
RESULTS

Baseline characteristics.
Pharmacokinetics. Two patients were excluded from the analysis of raltegravir at 400 mg QD, one due to fever on the pharmacokinetic study day and the other because the patient took the medication at the incorrect time before the intensive pharmacokinetic study day. The mean log plasma raltegravir concentrationtime curves for all patients on all three dosing regimens are plotted in Fig. 1 . The geometric mean and arithmetic mean pharmacokinetic parameters are summarized in Table 1 . There were significant differences in pharmacokinetic parameters between the three dosing regimens. Compared to the standard dosing of 400 mg BID, the 800-mg QD dosing had significantly higher values for AUC 0-24 , C max , and t 1/2 but a lower C trough (P Ͻ 0.001 for all). Reduction of the raltegravir dose to 400 mg QD led to a significant reduction in the time-adjusted AUC 0-24 , C trough , and t 1/2 values compared to those for the standard recommended dose of 400 mg BID (P Ͻ 0.001 for all). For all dosing regimens, no patient had an AUC below 4.0 mg-h/liter, with the exception of two patients with AUCs of 3.5 h-mg/liter and 3.96 h-mg/liter while on raltegravir at 400 mg BID. C trough was below 0.021 mg/liter in 9/17, 1/19, and 0/19 patients on raltegravir at 400 mg QD, 800 mg QD, and 400 mg BID, respectively. Table 2 shows the univariate analysis of factors affecting the raltegravir AUC, C max , C trough , and t 1/2 for the three dosing regimens. There was a 36% decrease in the AUC 0-24 when the dose was reduced from 400 mg BID to 400 mg QD (P Ͻ 0.001). A similar decrease was found for C trough (80%; P Ͻ 0.001). However, t 1/2 showed a significant increase of 79% (P Ͻ 0.001). When 800 mg QD was compared to 400 mg BID, there was a significant increase in C max (127%; P Ͻ 0.001) and t 1/2 (121%; P Ͻ 0.001) and a decrease in C trough (62%; P Ͻ 0.001).
Age, gender, body weight, calculated creatinine clearance, ALT, and tenofovir or lopinavir-ritonavir comedication did not affect the AUC of raltegravir in the univariate analysis. As expected, atazanavir comedication was associated with a higher AUC of raltegravir (113%) and a lower raltegravir clearance rate. The use of darunavir-ritonavir significantly increased the clearance of raltegravir.
In the multivariate analyses of changes in AUC, after adjusting for atazanavir comedication, there was a significant decrease in the geometric mean of the AUC (37%; P Ͻ 0.001) in the 400-mg QD dosing group compared to the standard 400-mg BID group, whereas there was no difference in the geometric mean of the AUC when patients were given 800 mg QD compared to 400 mg BID. The geometric mean of the AUC for patients treated with atazanavir was approximately 116% higher after adjusting for the raltegravir dosing regimen. There were significant increases in t 1/2 and decreases in clearance with the nonstandard raltegravir doses and with tenofovir and darunavir-ritonavir comedications. Table 3 compares the geometric mean ratios of AUC, C max , and C trough values for the three raltegravir dosing regimens in Thais in our study with those reported for Westerners taking raltegravir at 400 mg BID (14) . Using the same 400-mg BID dosing, our Thai patients had double the values for AUC, C max , and C trough compared to Westerners. Thais on raltegravir at 400 mg QD had an AUC that was 1.2 times that of Westerners on raltegravir at 400 mg BID, with an almost tripled C max and half the C trough . Raltegravir at 800 mg QD in Thais resulted in 2 times the AUC, 5 times the C max , and a similar C trough compared to those for raltegravir at 400 mg BID in Westerners.
Short-term virologic response and safety. All patients had plasma HIV RNA loads of Ͻ50 copies/ml at the end of all dosing regimens, and no serious adverse events were seen. There were no significant differences in ALT, creatinine clearance, TG, TC, and HDL after each dosing.
After a median (IQR) of 35 (33 to 39) weeks on raltegravir at 400 mg QD, 2 of 17 patients had confirmed HIV RNA loads of Ͼ50 copies/ml. The first patient had an HIV RNA rise 19 weeks after starting low-dose raltegravir, with an HIV RNA load of 95 copies/ml, and had a load of 126 copies/ml 10 weeks later. His raltegravir C trough at the time of full pharmacokinetic evaluation was 0.015 mg/liter. The second patient had an HIV RNA load of 239 copies/ml after 34 weeks of low-dose raltegravir, which was confirmed by an HIV RNA load of 123 copies/ml 4 weeks later. His C trough at the time of full pharmacokinetic analysis was 0.014 mg/ liter. An additional 3 patients had a single HIV RNA value above 50 copies/ml (51, 79, and 129 copies/ml), followed by HIV RNA suppression. Their raltegravir C trough concentrations at the time of full pharmacokinetic evaluation of low-dose raltegravir were 0.028, 0.060, and 0.006 mg/liter, respectively. The outcomes for patients with C trough values of Ͻ0.021 and Ն0.021 mg/liter at the time of the 400-mg QD pharmacokinetic study of raltegravir are summarized in Table 4 . There were approximately equal numbers of patients in each group, with slightly more females, persons with higher body weight, and persons who used PIs other than darunavir-ritonavir in the low-C trough group. The geometric mean for C trough was 0.014 mg/liter for the low-C trough group and 0.066 mg/liter for the high-C trough group. After about 9 months on low-dose raltegravir, virologic failure was seen only in the low-C trough group (22% versus 0% in the high-C trough group). The geometric mean C trough value continued to be lower in the low (n ϭ 8)-than in the high (n ϭ 6)-C trough group at the last follow-up visit.
DISCUSSION
Our study demonstrated that Thais had double the pharmacokinetic values of Westerners when the same 400-mg BID standard raltegravir dosing regimen was used. Importantly, low-dose raltegravir at 400 mg QD achieved similar AUC and C max values to a Merck provided data for Westerners who were enrolled in the published study of Markowitz et al. (14) . b Data are geometric means with 95% confidence intervals (CI) for Western subjects and geometric mean ratios with 95% CI for Thai subjects compared to Western subjects receiving 400 mg BID. Statistical comparisons were based on an unpaired t test of the geometric means, with standard deviations estimated from the reported 95% CI. AUC comparisons between twice-daily (BID) and once-daily (QD) dosing were made by first converting the AUC 0-12 to the AUC 0-24 . The C trough is C 12 for BID regimens and C 24 for QD regimens. *, P Ͻ 0.05; **, P Ͻ 0.001.
those observed in Westerners using the standard raltegravir dosing of 400 mg BID. For each of the 3 dosing regimens (raltegravir at 400 mg BID, 400 mg QD, and 800 mg QD), all subjects achieved the protocol-defined target AUC of Ն4.0 h-mg/liter and were able to maintain viral suppression below 50 copies/ml over the duration of the 6-week pharmacokinetic study. However, with a longer follow-up time of about 9 months on raltegravir at 400 mg QD, 2 of 17 patients had confirmed low-level viremia of 50 to 200 copies/ ml, which corresponded with having a C trough value below 0.021 mg/liter-a threshold extrapolated from the QDMRK study as showing an association with virologic failure risk (8, 23) .
Higher pharmacokinetic values in Thais than in Westerners have been shown for nucleoside reverse transcriptase inhibitors (NRTIs), NNRTIs, and PIs and are reported for the first time for raltegravir in this study. This is possibly due to differences in body weight, diet, and genetics between populations (2, 3, 6, 13, 17). Our findings show that Thais need less raltegravir to achieve similar pharmacokinetic values to those of Westerners, suggesting that low-dose raltegravir as maintenance therapy for Thais could be possible. Whether this is the case for other Asians or persons of low body weight is unknown.
The design of our study allowed for an unbiased and systematic pharmacokinetic comparison of three raltegravir dosing regimens in each individual. With the same total daily dosing, dosing at 800 mg QD had a similar adjusted AUC 0-24 but double the C max of dosing at 400 mg BID, which suggests a linear absorption. When the dose was halved to 400 mg QD, the adjusted AUC 0-24 was lower than that observed with the standard 400-mg BID dosing but was still above the protocol-defined AUC threshold. The main differences between the two QD dosing groups and the standard BID dosing group were the longer t 1/2 and the lower C trough with once-daily raltegravir. The longer t 1/2 could be due to better estimation of the terminal elimination phase and/or the inclusion of a circadian rhythm of slower drug metabolism during the night, which was not studied for the BID regimen, whereas the lower C trough could be from the longer terminal elimination phase. The result of t 1/2 estimation for BID and QD dosing is a composite of the initial and 2nd elimination phases, with a longer t 1/2 after QD dosing because more of the 2nd phase contributes to the t 1/2 estimation. Taking more samples in the 12-to 24-hour part of the curve would be ideal but is unpractical because it would require subjects to stay overnight. Consistent with published literature, age, gender, liver and renal function, and tenofovir and lopinavirritonavir comedication did not affect pharmacokinetic values (24) , but atazanavir significantly increased the raltegravir AUC (4, 7), likely owing to its inhibitory effect on UDP-glucuronosyltransferase-1A1, which metabolizes raltegravir (16) . Darunavirritonavir has been shown to decrease the raltegravir AUC by 29% (7). Such a trend was seen in our study, too, but the only significant finding was the longer raltegravir t 1/2 with concomitant darunavir-ritonavir therapy.
Recently, data from the QDMRK study indicated that treatment-naïve patients on raltegravir at 800 mg QD plus two NRTIs, with baseline HIV RNA loads above 100,000 copies/ml, had significantly lower antiviral responses than patients on raltegravir at 400 mg BID plus two NRTIs (8) . A pharmacokinetic/pharmaco- a All subjects had HIV RNA loads of Ͻ50 copies/ml at baseline and at the time of pharmacokinetic study. b Other antiretrovirals were administered at standard doses.
dynamic analysis showed that the majority of failures could be explained by high baseline HIV RNA loads and low raltegravir C trough values (23) . Although no formal cutoff for raltegravir C trough was given by the investigators, patients with C trough values in the lowest quartile (0.003 to 0.021 mg/liter) had significantly lower antiviral responses than patients with values in the other quartiles. In our study patients, this was the case in 9/17, 1/19, and 0/19 patients while on raltegravir at 400 mg QD, 800 mg QD, and 400 mg BID, respectively. Notably, our study differs in two major aspects from the QDMRK study, namely, (i) maintenance versus initial therapy and (ii) QD dosing of raltegravir with a PI and 1 or 2 NRTIs versus QD dosing of raltegravir with two NRTIs. Our data suggest that low-level viremia with low-dose raltegravir (400 mg QD) was likely due to the low C trough rather than the low total daily dosing. At the last follow-up visit, about 9 months after beginning raltegravir at 400 mg QD, one-fifth of patients in the low-C trough (Ͻ0.021 mg/liter) group had confirmed virologic failure, while none of the patients with C trough values of Ն0.021 mg/liter had failure. The QDMRK study showed an association between a low raltegravir C trough and virologic failure only for the QD, not BID, raltegravir regimens (8) . We would have chosen to study raltegravir at 200 mg BID or 300 mg BID if these formulations were available, but this was not the case. This forced us to study a 50% dose reduction in both daily dose and dose frequency. Although low-level viremia of Ͻ200 copies/ml may not be clinically significant (18), we resumed raltegravir at 400 mg BID immediately in such patients, as their future drug options are limited. Raltegravir is not available as part of the Thai government universal health care program, and the monthly cost of raltegravir is around $530, 3 times the average Thai household monthly income. Our patients faced the prospect of interrupting raltegravir therapy due to a lack of funds. With dose selection studies consistently showing good virologic efficacy with doses as low as 100 mg BID in treatment-naïve patients (10, 14, 15) , coupled with the adequate AUC 0-24 obtained using raltegravir at 400 mg QD, we felt that low-dose raltegravir at 400 mg QD could be an option for our patients and those in similar settings. A copayment system of the HIV-NAT drug fund was used to ensure an uninterrupted supply of raltegravir for these patients (1). Even with monthly HIV RNA monitoring at $70 per test and transportation reimbursement at $20 per visit from the HIV-NAT drug fund, significant savings are gained with low-dose raltegravir maintenance therapy, allowing for more patients to be treated.
In summary, Thai patients had higher raltegravir pharmacokinetic values than Westerners, and low-dose raltegravir could be a cost-saving maintenance therapy option. However, once daily, low-dose raltegravir at 400 mg QD is associated with a low raltegravir C trough and subsequent risk for low-level viremia. Therefore, such a regimen should not be used in settings where raltegravir therapeutic drug monitoring and frequent HIV RNA monitoring are not possible, nor should it be attempted in patients with detectable HIV viremia. However, if low-dose raltegravir for maintenance therapy is needed to help more patients access raltegravir, C trough monitoring could assist in dose selection and determining the frequency of HIV RNA monitoring. In addition, further work should be done to evaluate the relationship of C trough and HIV RNA load in a greater number of Thai patients on raltegravir therapy at 400 mg QD. Since C trough is generally higher with BID than QD regimens, a reduced raltegravir dosing regimen of 200 mg or 300 mg BID would be preferred, and such formulations should be manufactured and studied. The ability to safely reduce the raltegravir dose by half could allow more people in low-and middle-income countries to receive this drug when their initial regimens fail.
